ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Ann Thorac Surg 2008;86:1450-1457. doi:10.1016/j.athoracsur.2008.07.043
© 2008 The Society of Thoracic Surgeons
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Todd M. Dewey
David L. Brown
William H. Ryan
Syma L. Prince
Michael J. Mack
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dewey, T. M.
Right arrow Articles by Mack, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dewey, T. M.
Right arrow Articles by Mack, M. J.
Related Collections
Right arrow Valve disease

Original Articles: Adult Cardiac

High-Risk Patients Referred for Transcatheter Aortic Valve Implantation: Management and Outcomes

Todd M. Dewey, MDa,b,*, David L. Brown, MDa,b, Tony S. Das, MDa, William H. Ryan, MDa, Jill E. Fowler, RN, BSNa, Shannon D. Hoffman, RNa, Syma L. Prince, RN, BSNa, Morley A. Herbert, PhDb, Dan Culica, MD, PhDa, Michael J. Mack, MDa,b

a Cardiopulmonary Research Science and Technology Institute, Dallas, Texas
b Medical City Dallas Hospital, Dallas, Texas

Accepted for publication July 16, 2008.

* Address correspondence to Dr Dewey, 7777 Forest Lane, Suite A323, Dallas, TX 75230 (Email: tdewey{at}CSANT.com).

Presented at the Forty-fourth Annual Meeting of The Society of Thoracic Surgeons, Ft. Lauderdale, FL, Jan 28–30, 2008.

Background: Aortic valve replacement (AVR) is the treatment of choice for critical aortic stenosis. Selected patients have not previously been referred for AVR because of excessive risk of mortality and morbidity with surgery. The option of transcatheter aortic valve implantation (TAVI) has increased referral of this high-risk cohort for therapeutic intervention. We report the management and outcomes of these patients.

Methods: Patients referred for TAVI from December 2005 to December 2007 were evaluated and followed up for intermediate-term all cause mortality. Patients received medical management, TAVI, conventional AVR, or balloon valvuloplasty (BAV) based on risk profile, hemodynamic and echocardiographic criteria, physician judgment, or patient choice. Patients were compared for demographics, Society of Thoracic Surgeons predicted risk of mortality score, and outcomes after AVR, TAVI, or BAV.

Results: One hundred five patients were referred for TAVI during a 24-month period. Fifty-two patients (49.5%) received medical management, 16 (15.2%) conventional AVR, 21 (20.0%) received TAVI, and 16 (15.2%) received BAV. Patients were classified as medical management because of physician or patient choice, not meeting TAVI criteria, or underevaluation for a possible procedure. For all patients the average length of follow-up was 159 ± 147 days. Patients receiving BAV had a Society of Thoracic Surgeons predicted risk of mortality score greater than those having medical management, AVR, or TAVI. Thirty-day mortality was 1 of 16 patients (6.3%) for AVR, 2 of 21 patients (9.5%) with TAVI, 2 of 16 patients (12.5%) for BAV, and 7 of 52 patients (13.5%) for the medical management cohort. Overall mortality during follow-up was 42.3% (22 of 52 patients) for medical management, 19.1% (4 of 21 patients) for TAVI, 12.5% (2 of 16 patients) for AVR, and 37.5% (6 of 16 patients) for BAV.

Conclusions: The population of patients screened for transcatheter therapy is complex and heterogeneous. Medical management alone demonstrates a high mortality rate, and BAV, although providing transient symptomatic relief, does not favorably impact survival. The majority of referred patients (65.7%), including those that declined intervention, were candidates for some form of valve replacement therapy, either TAVI or AVR. Transcatheter aortic valve implantation can be performed in appropriately selected patients with good early and immediate-term outcomes.




This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
D. H. Adams, A. C. Anyanwu, J. Chikwe, and F. Filsoufi
The Year in Cardiovascular Surgery
J. Am. Coll. Cardiol., June 23, 2009; 53(25): 2389 - 2403.
[Full Text] [PDF]

Home page
 JRSMHome page
M. L Field, J. Sammut, M. Kuduvalli, A. Oo, and A. Rashid
Hybrid theatres: nicety or necessity?
J R Soc Med, March 1, 2009; 102(3): 92 - 97.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2008 by The Society of Thoracic Surgeons.